Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum J26
- Development stage
- Preclinical
- Lead developer
- Junyao Health
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum J26 is a probiotic bacterial strain isolated from Chinese traditional fermented dairy products. It exhibits significant immunomodulatory activity by regulating the expression of immune-related genes, including upregulation of cytokines such as IL-1α, IL-1β, IL-6, and TNF-α in the intestinal tract. The strain produces teichoic acids that are key molecules involved in modulating host immune responses[1]. L. plantarum J26 has demonstrated beneficial effects in animal models for alleviating alcohol-induced liver injury by reducing Gram-negative pathogenic bacteria abundance, maintaining intestinal barrier integrity, and inhibiting TLR4-mediated MAPK signaling to reduce liver inflammation[5][6]. Additionally, postbiotics derived from this strain (J26P) have shown efficacy in lowering cholesterol and improving metabolic parameters via regulation of the LXRα–CYP7A1–bile acid excretion pathway in hypercholesterolemic mice[7]. Its mechanisms also include increasing short-chain fatty acid production and activating Nrf2 signaling to alleviate oxidative stress[6].
- Other names
- Lactiplantibacillus plantarum J26
Beyond the preview
Go deeper on Lactobacillus plantarum J26.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum J26.